A Formalin-Fixed, Paraffin-Processed Cell Line Standard for Quality Control of Immunohistochemical Assay of HER-2/neu Expression in Breast Cancer
Open Access
- 1 January 2002
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 117 (1), 81-89
- https://doi.org/10.1309/4ncm-qj9w-qm0j-6qje
Abstract
To ensure the accuracy and reproducibility of immunohistochemical assays for determining HER-2/neu status of patients with breast cancer, a reliable standard for monitoring assay sensitivity is necessary. We optimally fixed and paraffin processed human ovarian and breast carcinoma cell lines SKOV-3, MDA-MB-453, BT-20, and MCF-7 in quantities sufficient to meet the needs of a laboratory for the foreseeable future. The material was tested, alongside HercepTest kit cell lines (DAKO, Carpinteria, CA), by 7 breast cancer centers in the United Kingdom and France with different immunohistochemical assays and markers. The cell lines also were analyzed by fluorescence in situ hybridization (FISH) by 2 centers using HER-2/neu kits. FISH produced 100% agreement between the 2 centers: SKOV-3 and MDA-MB-453 showed HER-2/neu amplification and BT-20 and MCF-7 did not. Immunohistochemical analysis and a common evaluation method produced 100% agreement that SKOV-3 and MCF-7 showed 3+ and zero HER-2/neu overexpression, respectively. For MDA-MB-453, there was 71% (5/7) concordance of 2+ immunohistochemical staining and 86% (6/7) concordance of zero or 1+ staining for BT-20. The cell lines provide a valuable standard for gauging HER-2/neu assay sensitivity irrespective of the antibody, antigen retrieval system, detection system, or method of evaluation used.Keywords
This publication has 26 references indexed in Scilit:
- Study of Interlaboratory Reliability and Reproducibility of Estrogen and Progesterone Receptor Assays in EuropeAmerican Journal of Clinical Pathology, 2001
- Recommendations for HER2 testing in the UKJournal of Clinical Pathology, 2000
- Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast CarcinomaLaboratory Investigation, 2000
- Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countriesJournal of Clinical Pathology, 2000
- Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systemsJournal of Clinical Pathology, 2000
- HER-2/neu Protein Expression in Breast Cancer Evaluated by ImmunohistochemistryAmerican Journal of Clinical Pathology, 2000
- Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ HybridizationLaboratory Investigation, 2000
- The Quality of Her-2/Neu Predictive Immunohistochemistry: Something FISHy?Laboratory Investigation, 2000
- Loss of Tumor Marker-Immunostaining Intensity on Stored Paraffin Slides of Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987